FDA Extends Tinlarebant Review to May 2027

Company Belite Bio Event Type FDA review extension (PDUFA date moved from Feb 12 to May 12, 2027) Modality Oral small molecule Asset Tinlarebant Target Retinol-binding protein 4 Disease Area Stargardt disease type 1 Summary Belite Bio disclosed November 20 that FDA extended the review…

🔒

Continue reading this signal

Create a free InSilens account to unlock full articles, analysis, and deal context.

Create Free Account
Share this article :

Leave a Reply

Your email address will not be published. Required fields are marked *